Edwards Lifesciences VP Donald E. Bobo, Jr. Sells 6,500 Shares

Donald E. Bobo, Jr., the Vice President of Edwards Lifesciences Co. (NYSE:EW), executed a sale of 6,500 shares of the company's stock on February 13th. The transaction was carried out at an average price of $75.75 per share, resulting in a total sale amount of $492,375. Following this sale, Bobo now holds 46,936 shares in the company, which are currently valued at approximately $3,555,402. This sale marks a 12.16% reduction in his ownership stake in the firm. The details of this transaction were filed with the Securities and Exchange Commission (SEC), making them publicly available.

Current Stock Performance

As of the last market opening, shares of Edwards Lifesciences were priced at $75.96. Over the past year, the stock has seen a low of $58.93 and a high of $96.12. The company boasts a market capitalization of around $44.80 billion, with a price-to-earnings ratio of 10.96, a PEG ratio of 3.64, and a beta of 1.10. The firm's 50-day moving average is $72.51, while the 200-day moving average stands at $69.36. Additionally, the company possesses a strong financial position with a debt-to-equity ratio of 0.06, quick ratio of 2.89, and current ratio of 3.46.

Financial Report Highlights

On February 11th, Edwards Lifesciences reported its latest quarterly earnings. The firm posted earnings per share (EPS) of $0.59, which exceeded industry analysts' expectations of $0.55 by $0.04. The company's return on equity was reported at 20.76%, with a net margin of 70.82%. Looking ahead, analysts forecast that Edwards Lifesciences will achieve an EPS of 2.56 for the current fiscal year.

Analysis and Analyst Ratings

There have been various analyst reports concerning Edwards Lifesciences recently. Bank of America upgraded the company's rating from "neutral" to "buy" and raised their target price from $82.00 to $90.00. Conversely, Wolfe Research downgraded the stock from a "peer perform" rating to "underperform", setting a target price of $60.00. Additionally, Sanford C. Bernstein increased their rating from "strong sell" to "hold". Piper Sandler adjusted their target price from $70.00 to $73.00, maintaining a "neutral" stance, while Evercore ISI lowered their target to $73.00 and left an "in-line" rating for the stock. Currently, one analyst rates the stock as a sell, fourteen give it a hold rating, and twelve suggest a buy. Overall, the consensus rating is categorized as "Hold" with an average target price set at $79.95.

Institutional Ownership Trends

Several major investors have recently adjusted their holdings in Edwards Lifesciences. Notably, Crowley Wealth Management Inc. acquired a new stake valued at approximately $26,000 in the fourth quarter. Similarly, Millstone Evans Group LLC and FSA Wealth Management LLC also entered positions, with estimated values around $29,000 and $30,000 respectively. Institutional investors collectively own about 79.46% of the stock.

About Edwards Lifesciences

Edwards Lifesciences Corporation specializes in providing products and technologies that address structural heart diseases and critical care monitoring both in the U.S. and internationally, including in Europe and Asia. The company's offerings include transcatheter heart valve replacement products, which facilitate minimally invasive aortic heart valve replacements under the Edwards SAPIEN brand, as well as valve repair and replacement solutions for mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband brands.

Edwards, shares, stock, sale, financials